Cancer-test maker Genomic Health (NASDAQ: GHDX)started the year on a high note, posting double-digit revenue growth, and would have turned a profit if not for an $8.5 million one-time charge for stopping development of the Oncotype SEQ Liquid Select test, which was announcedon the last quarterly call.
Genomic Health Starts the Year off Right
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться